WO2023202730A3 - 放射性伊文思蓝衍生物药物水溶液及其制备方法和用途 - Google Patents
放射性伊文思蓝衍生物药物水溶液及其制备方法和用途 Download PDFInfo
- Publication number
- WO2023202730A3 WO2023202730A3 PCT/CN2023/101452 CN2023101452W WO2023202730A3 WO 2023202730 A3 WO2023202730 A3 WO 2023202730A3 CN 2023101452 W CN2023101452 W CN 2023101452W WO 2023202730 A3 WO2023202730 A3 WO 2023202730A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aqueous solution
- radioactive
- evans blue
- preparation
- method therefor
- Prior art date
Links
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical class CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 title abstract 3
- 239000007864 aqueous solution Substances 0.000 title abstract 3
- 230000002285 radioactive effect Effects 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 abstract 2
- 229940121896 radiopharmaceutical Drugs 0.000 abstract 2
- 239000012217 radiopharmaceutical Substances 0.000 abstract 2
- 230000002799 radiopharmaceutical effect Effects 0.000 abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 229960003699 evans blue Drugs 0.000 abstract 1
- 229960005219 gentisic acid Drugs 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
本申请涉及放射性药物水溶液及其用途，所述放射性药物水溶液包括经伊文思蓝(EB)片段修饰的靶向分子与放射性金属核素形成的络合物以及稳定剂，所述稳定剂优选为龙胆酸、乙醇、甲硫氨酸中的一种或两种以上。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210416297.4 | 2022-04-20 | ||
| CN202210416293.6A CN114748471A (zh) | 2022-04-20 | 2022-04-20 | 放射性标记的伊文思蓝衍生物药物的制备方法及用途 |
| CN202210416293.6 | 2022-04-20 | ||
| CN202210416297.4A CN114796532A (zh) | 2022-04-20 | 2022-04-20 | 放射性标记的伊文思蓝衍生物药物水溶液及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2023202730A2 WO2023202730A2 (zh) | 2023-10-26 |
| WO2023202730A3 true WO2023202730A3 (zh) | 2023-12-14 |
Family
ID=88419308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2023/101452 WO2023202730A2 (zh) | 2022-04-20 | 2023-06-20 | 放射性伊文思蓝衍生物药物水溶液及其制备方法和用途 |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2023202730A2 (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020021310A1 (en) * | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) Srl | Stable, concentrated radionuclide complex solutions |
| CN111542518A (zh) * | 2017-10-03 | 2020-08-14 | 由卫生与公众服务部部长代表的美利坚合众国 | 埃文斯蓝衍生物的化学缀合物及其作为放射治疗剂和成像剂的用途 |
| CN114748471A (zh) * | 2022-04-20 | 2022-07-15 | 北京先通国际医药科技股份有限公司 | 放射性标记的伊文思蓝衍生物药物的制备方法及用途 |
| CN114796532A (zh) * | 2022-04-20 | 2022-07-29 | 北京先通国际医药科技股份有限公司 | 放射性标记的伊文思蓝衍生物药物水溶液及其用途 |
-
2023
- 2023-06-20 WO PCT/CN2023/101452 patent/WO2023202730A2/zh unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111542518A (zh) * | 2017-10-03 | 2020-08-14 | 由卫生与公众服务部部长代表的美利坚合众国 | 埃文斯蓝衍生物的化学缀合物及其作为放射治疗剂和成像剂的用途 |
| WO2020021310A1 (en) * | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) Srl | Stable, concentrated radionuclide complex solutions |
| CN114748471A (zh) * | 2022-04-20 | 2022-07-15 | 北京先通国际医药科技股份有限公司 | 放射性标记的伊文思蓝衍生物药物的制备方法及用途 |
| CN114796532A (zh) * | 2022-04-20 | 2022-07-29 | 北京先通国际医药科技股份有限公司 | 放射性标记的伊文思蓝衍生物药物水溶液及其用途 |
Non-Patent Citations (3)
| Title |
|---|
| DE BLOIS ERIK, CHAN HO SZE, DE ZANGER RORY, KONIJNENBERG MARK, BREEMAN WOUTER A.P.: "Application of single-vial ready-for-use formulation of 111In- or 177Lu-labelled somatostatin analogs", APPLIED RADIATION AND ISOTOPES, ELSEVIER, OXFORD., GB, vol. 85, 1 February 2014 (2014-02-01), GB , pages 28 - 33, XP093117067, ISSN: 0969-8043, DOI: 10.1016/j.apradiso.2013.10.023 * |
| WANG, ZHANTONG ET AL.: "Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors", BIOCONJUGATE CHEMISTRY, vol. 29, 14 August 2018 (2018-08-14), pages 3213 - 3221, XP055849080, DOI: 10.1021/acs.bioconjchem.8b00556 * |
| WEN XUEJUN, XU PENGFEI, SHI MENGQI, LIU JIA, ZENG XINYING, ZHANG YIREN, SHI CHANGRONG, LI JINGCHAO, GUO ZHIDE, ZHANG XIANZHONG, KH: "Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics", THERANOSTICS, IVYSPRING INTERNATIONAL PUBLISHER, AU, vol. 12, no. 1, 1 January 2022 (2022-01-01), AU , pages 422 - 433, XP093117064, ISSN: 1838-7640, DOI: 10.7150/thno.68182 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023202730A2 (zh) | 2023-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121877T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει πιμοβενδανη | |
| Ma et al. | Silver-catalyzed fluoroalkylation of thiols using fluoroalkanesulfinates | |
| EP3185912B1 (en) | Mono-, di- or polysaccharide used as metal inhibitor in the preparation of 68ga-chelate-functionalized targeting agent | |
| BR9815423A (pt) | Composto derivado de imidazol, processo para preparar um derivado de imidazol, e, composição farmacêutica. | |
| HRP20050399B1 (hr) | Novi postupci za dobivanje roflumilasta | |
| RS54508B1 (en) | A METHOD FOR THE PRODUCTION OF DISSOLVED EXTREMELY PURE 177 LU UNITS (177 LUTECIUM) AND DISSOLVED 177 LU UNITS | |
| NO20024772L (no) | Percyquinnin, fremgangsmÕte for dets fremstilling og dets anvendelse som et legemiddel | |
| MX349070B (es) | Preparacion y/o formulacion de proteinas reticuladas con polisacaridos. | |
| BR112022012385A2 (pt) | Método de preparação e aplicação de composto de agente de degradação de proteínas | |
| EA201791350A9 (ru) | Радиофармацевтические комплексы | |
| NO20076425L (no) | Fremgangsmater for behandling av drug-resistent cancer | |
| NO20076592L (no) | Stabilt aktivt-stoffkompleks av salter av o-acetylsalicylsyre med basiske aminosyrer og glycin | |
| DK1467706T3 (da) | Dermalt applikationssystem for aminolevulinsyre-derivater | |
| MX2021013055A (es) | Inhibidores de antigenos de membrana especificos de prostata (psma) como agentes diagnosticos y terapeuticos con radionuclidos. | |
| Hoegl et al. | Stereochemical modification of geminal dialkyl substituents on pantothenamides alters antimicrobial activity | |
| MY165211A (en) | An improved process for preparation of physiologically active polypeptide complex | |
| WO2015051276A1 (en) | Small molecule securinine and norsecurinine analogs and their use in inhibiting myeloperoxidase | |
| BR0311222A (pt) | R-enantiÈmeros de derivados de piranoindol contra hepatite c, seu método de obtenção e composição farmacêutica compreendendo os mesmos | |
| CY1113781T1 (el) | Παραγωγα της ασιμαδολινης με ομοιοπολικα συνδεδεμενα οξεα | |
| WO2023202730A3 (zh) | 放射性伊文思蓝衍生物药物水溶液及其制备方法和用途 | |
| WO2007005056A3 (en) | Platinum complexes with mononitrile-containing ligands | |
| CO6430466A2 (es) | Derivados de pirazolopirimidina triciclicos | |
| Weisell et al. | Charge deficient analogues of the natural polyamines | |
| ZA202303913B (en) | Pyrimidine carboxamide compound and application thereof | |
| WO2023191839A3 (en) | Stabilized compositions of radionuclides and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23791382 Country of ref document: EP Kind code of ref document: A2 |